Ergotamine in the acute treatment of migraine: a review and European consensus.

Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.

[1]  S. Silberstein,et al.  Safety and Efficiency of Ergotamine Tartrate and Dihydroergotamine in the Treatment of Migraine and Status Migrainosus. , 1995, Neurology.

[2]  M. Wilkinson.  THE TREATMENT OF ACUTE MIGRAINE ATTACKS , 1976 .

[3]  L. Liversedge,et al.  A Double‐blind Crossover Trial of Isometheptene mucate Compound and Ergotamine in Migraine , 1972, The British journal of clinical practice.

[4]  L. Liaudet,et al.  Drug points: severe ergotism associated with interaction between ritonavir and ergotamine. , 1999, BMJ.

[5]  J. Palacios,et al.  Characterization of 5‐HT receptors on human pulmonary artery and vein: functional and binding studies , 1997, British journal of pharmacology.

[6]  D. Evans,et al.  Peripheral Vascular Effects and Pharmacokinetics of the Antimigraine Compound, Zolmitriptan, in Combination with Oral Ergotamine in Healthy Volunteers , 1997, Cephalalgia : an international journal of headache.

[7]  R. Dart,et al.  Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. , 1996, Archives of internal medicine.

[8]  A. Simon,et al.  Cholesterol lowering therapy inhibits the low-flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects. , 1996, British journal of clinical pharmacology.

[9]  H. Kaube,et al.  Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. , 1996, Brain : a journal of neurology.

[10]  P. Saxena,et al.  Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. , 1979, European journal of pharmacology.

[11]  Ferrari,et al.  Guidelines for Controlled Trials of Drugs in Migraine: Second Edition , 2000, Cephalalgia : an international journal of headache.

[12]  B. Gustafsson,et al.  A Comparative Trial of Ergotamine Tartrate, Acetyl Salicylic Acid and a Dextropropoxyphene Compound in Acute Migraine Attacks , 1978, Headache.

[13]  B. Stötzel,et al.  Drug points , 2002 .

[14]  J. Feighner,et al.  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks , 1998, Neurology.

[15]  L. Paalzow,et al.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. , 1983, British journal of clinical pharmacology.

[16]  R. Ryan.  DOUBLE‐BLIND CLINICAL EVALUATION OF THE EFFICACY AND SAFETY OF ERGOSTINE‐CAFFEINE, ERGOTAMINE‐CAFFEINE, AND PLACEBO IN MIGRAINE HEADACHE , 1970, Headache.

[17]  J. Graham,et al.  Development of tolerance to ergot alkaloids in a patient with unusually severe migraine. , 1949, The New England journal of medicine.

[18]  T. Treves,et al.  Naproxen Sodium Versus Ergotamine Tartrate in the Treatment of Acute Migraine Attacks , 1992, Headache.

[19]  M. Moskowitz,et al.  Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater , 1991, British journal of pharmacology.

[20]  J. Lance,et al.  A Randomized, Double-Blind Comparison of Sumatriptan and Cafergot in the Acute Treatment of Migraine , 1991 .

[21]  A F Cohen,et al.  Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response , 1996, Clinical pharmacology and therapeutics.

[22]  V. Pfaffenrath,et al.  Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan , 1998, Headache.

[23]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[24]  B. Galer,et al.  Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature Review , 1991, Headache.

[25]  P. Saxena,et al.  Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5‐HT1B/1D receptors and α2‐adrenoceptors , 1999, British journal of pharmacology.

[26]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[27]  P. Goadsby,et al.  The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.

[28]  C. Weiller,et al.  Brain stem activation in spontaneous human migraine attacks , 1995, Nature Medicine.

[29]  T. Erkinjuntti,et al.  Placebo-Controlled Double-Blind Trial of Pirprofen and an Ergotamine Tartrate Compound in Migraine Attacks , 1988, Cephalalgia : an international journal of headache.

[30]  W. H. Aellig,et al.  Ergot Alkaloids and Related Compounds , 1978, Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie.

[31]  U. Christians,et al.  Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. , 1996, British journal of clinical pharmacology.

[32]  A. Ostfeld.  A STUDY OF MIGRAINE PHARMACOTHERAPY , 1961, The American journal of the medical sciences.

[33]  A. Rascol,et al.  Acute Migraine Attack Therapy: Comparison of Naproxen Sodium and an Ergotamine Tartrate Compound , 1985, Cephalalgia : an international journal of headache.

[34]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[35]  J. Saper,et al.  Aborting a Migraine Attack: Naproxen Sodium v Ergotamine plus Caffeine , 1988, Headache.

[36]  J. Olesen,et al.  5-Hydroxytryptamine mechanisms in primary headaches , 1994 .

[37]  E. Müller-Schweinitzer,et al.  Basic Pharmacological Properties , 1978 .

[38]  P. Tfelt-Hansen,et al.  Comparison of Pharmacodynamic Effects and Plasma Levels of Oral and Rectal Ergotamine , 1986, Cephalalgia : an international journal of headache.

[39]  T. J. C. Storch.  COMPLICATIONS FOLLOWING THE USE OF ERGOTAMINE TARTRATE: THEIR RELATION TO THE TREATMENT OF MIGRAINE HEADACHE , 1938 .

[40]  J. Laínez,et al.  Comparative Efficacy and Safety of Calcium Carbasalate plus Metoclopramide versus Ergotamine Tartrate plus Caffeine in the Treatment of Acute Migraine Attacks , 1999, European Neurology.

[41]  N. Mathew,et al.  Transformation of Episodic Migraine Into Daily Headache: Analysis of Factors , 1982, Headache.

[42]  M. Ferrari,et al.  Sumatriptan in clinical practice , 1996, Neurology.

[43]  J. Heiligers,et al.  Characterization of 5‐HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5‐HT1B/1D and novel receptors , 1998, British journal of pharmacology.

[44]  W. Waters.  Controlled Clinical Trial of Ergotamine Tartrate , 1970, British medical journal.

[45]  Naide.  Complications following the use of ergotamine tartrate , 1939 .

[46]  E. Mikkelsen,et al.  Effects of 5-Hydroxytryptamine and Ergotamine on Human Superficial Temporal Artery , 1981, Cephalalgia : an international journal of headache.

[47]  P. Marsden,et al.  A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography , 1997, Neurology.

[48]  J. Lonnqvist,et al.  Antidepressants and suicide , 1994, BMJ.

[49]  H. Quiding,et al.  Mild Analgesics as an Alternative to Ergotamine in Migraine. A Comparative Trial with Acetylsalicylic Acid, Ergotamine Tartrate, and a Dextropropoxyphene Compound , 1980, Journal of clinical pharmacology.

[50]  D. Hoyer.  Functional correlates of serotonin 5-HT1 recognition sites. , 1988, Journal of receptor research.

[51]  P. Tfelt-Hansen,et al.  The Effect of Ergotamine and Dihydroergotamine on Cerebral Blood Flow in Man , 1985, Stroke.

[52]  C. Dahlöf.  Placebo-Controlled Clinical Trials with Ergotamine in the Acute Treatment of Migraine , 1993, Cephalalgia : an international journal of headache.

[53]  M. Moskowitz,et al.  Evidence for 5-HT1B/1D Receptors Mediating the Antimigraine Effect of Sumatriptan and Dihydroergotamine , 1991, Cephalalgia : an international journal of headache.

[54]  W. Brass,et al.  Clinical Trial of Inhaled Ergotamine Tartrate in Migraine , 1964, British medical journal.

[55]  W. Amery,et al.  The Pharmacological basis of migraine therapy , 1984 .

[56]  M. Ferrari,et al.  Risk Factors for Headache Recurrence After Sumatriptan: A Study in 366 Migraine Patients , 1996, Cephalalgia : an international journal of headache.

[57]  H. Dale.  On some physiological actions of ergot , 1906, The Journal of physiology.

[58]  R. Kaaja,et al.  Ketoprofen and ergotamine in acute migraine , 1992, Journal of internal medicine.

[59]  H. Diener,et al.  Headache after frequent use of serotonin agonists zolmitriptan and naratriptan , 1999, The Lancet.

[60]  G. Gothoni,et al.  TOLFENAMIC ACID IS AS EFFECTIVE AS ERGOTAMINE DURING MIGRAINE ATTACKS , 1979, The Lancet.

[61]  B. Johnston,et al.  THE EFFECT OF ERGOTAMINE ON TISSUE BLOOD FLOW AND THE ARTERIOVENOUS SHUNTING OF RADIOACTIVE MICROSPHERES IN THE HEAD , 1978, British Journal of Pharmacology.

[62]  P. Goadsby.  Serotonin 5-HT1B/1D Receptor Agonists in Migraine , 1998 .

[63]  H. Kao,et al.  Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Glusa,et al.  Endothelial 5‐HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine , 1996, British journal of pharmacology.

[65]  The Effect of Ergotamine and Dihydroergotamine on Cerebral Blood Flow in Man , 1985 .

[66]  P. Taugher.  Migraine: a review. , 1963, Marquette medical review.

[67]  J. Leysen,et al.  Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. , 1996, Molecular pharmacology.

[68]  A. Friedman,et al.  Ergotamine tolerance in patients with migraine. , 1955, Journal of the American Medical Association.

[69]  Manjit,et al.  Neurology , 1912, NeuroImage.

[70]  T. Gnecchi-Ruscone,et al.  Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease. , 1998, The American journal of cardiology.

[71]  Friedman Ap,et al.  Symptomatic relief of migraine: multicenter comparison of Cafergot P-B, Cafergot, and placebo. , 1989 .

[72]  Horton Bt,et al.  Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. , 1951 .